Forte Biosciences (FBRX) Net Equity Issued and Repurchased (2016 - 2025)

Forte Biosciences (FBRX) has reported Net Equity Issued and Repurchased for 9 consecutive years, with -$73.2 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$73.2 million; the TTM figure through Dec 2025 stood at -$73.2 million (changed N/A YoY), while the FY2025 annual figure was $1.8 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased fell to -$73.2 million in Q3 2025 per FBRX's latest filing, from $8000.0 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $25.0 million in Q1 2022 and bottomed at -$73.2 million in Q3 2025.
• Historically, Net Equity Issued and Repurchased has averaged -$1.1 million across 4 years, with a median of $7.7 million in 2022.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 221.9% in 2023 and fell as far as 99.98% in 2023.
• Forte Biosciences' Net Equity Issued and Repurchased stood at $7.7 million in 2022, then soared by 221.9% to $24.8 million in 2023, then sank by 99.97% to $8000.0 in 2024, then plunged by 915362.5% to -$73.2 million in 2025.
• Business Quant data shows FBRX's Net Equity Issued and Repurchased at -$73.2 million in Q3 2025, $8000.0 in Q1 2024, and $24.8 million in Q3 2023.